Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Breast Neoplasms × Exercise × Clear all

Phase

Phase NA 92 Phase 3 6 Phase 2 5 Phase EARLY_PHASE1 1 Phase 2/3 1 Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1 Breast 1

Conditions

Motor Activity 3 Prostatic Neoplasms 1 Obesity 1 Head and Neck Neoplasms 1 Colonic Neoplasms 1 Colon Cancer Prevention 1 Breast Neoplasms 1 Breast Cancer Prevention 1

Interventions

Capecitabine 13 Paclitaxel 9 Cyclophosphamide 9 Docetaxel 8 Epirubicin 7 Gemcitabine 5 Doxorubicin 5 Trastuzumab 4 Letrozole 4 Carboplatin 4 pertuzumab 3 exemestane 3 Vinorelbine 3 AC protocol 3 Thiotepa 2 Taxes 2 Neoadjuvant Therapy 2 Melatonin 2 Lapatinib 2 Fluorouracil 2 Drug Therapy 2 Cisplatin 2 Albumin-Bound Paclitaxel 2 Ado-Trastuzumab Emtansine 2 130-nm albumin-bound paclitaxel 2 taxane 1 soluble LAG-3 protein, human 1 pyrotinib 1 pitavastatin 1 palbociclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00393172 2019-11-01

WISER

University of Minnesota

Phase 2/3 Completed

Breast Neoplasms, Motor Activity, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡